The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The accelerated review covers WCK 5222 for multiple critical infections
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Subscribe To Our Newsletter & Stay Updated
